Skip to main content

SELLAS Life Sciences Group, Inc.

SLS
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001390478

No open-market purchases or sales by SELLAS Life Sciences Group, Inc. insiders were filed in the last 90 days; 193 institutions reported holding it in 13F filings for Q2 2026, worth $1.08B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by SELLAS Life Sciences Group, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for SELLAS Life Sciences Group, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for SELLAS Life Sciences Group, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Stergiou Angelos M.President and CEO1,759,183Jun 18, 20262
Van Nostrand Robert LDirector82,900Jan 9, 20261
Scheinberg David ADirector73,082Jan 9, 20261
Wasman JaneDirector92,900Jan 9, 20261
Varian JohnDirector72,900Jan 9, 20261
Cicic DraganSVP, Chief Development Officer557,805Jan 9, 20262
Burns John ThomasCFO554,327Jan 9, 20262
Kalin Katherine BachDirector154,400Jan 9, 20262
Wood Barbara AEVP, Gen. Counsel, Corp. Sec.117,225Jan 25, 20240
Francomano RobertChief Commercial Officer40,918Jan 25, 20240

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Nov 21, 2025 (view filing)Nov 192 daysKalin Katherine BachDirectorPPurchase+63.4K$1.59+$100.8K+154.6%104.4K after
Jun 13, 2025 (view filing)Jun 121 dayVan Nostrand Robert LDirectorPPurchase+10.0K$1.48+$14.8K+96.2%20.4K after
Jun 2, 2025 (view filing)May 303 daysWasman JaneDirectorPPurchase+20.0K$1.69+$33.8K+192.3%30.4K after
May 22, 2025 (view filing)May 22Same dayKalin Katherine BachDirectorPPurchase+20.0K$1.80+$36.0K+95.2%41.0K after
Dec 5, 2022 (view filing)Dec 5Same dayStergiou Angelos M.President and CEOSSaleClass A Common Stock−6.49K$2.61−$16.9K−3.9%161.7K after
Dec 5, 2022 (view filing)Dec 5Same dayBurns John ThomasSenior VP, Finance & CAOSSaleClass A Common Stock−1.16K$2.59−$3.00K−3.8%29.3K after
Dec 5, 2022 (view filing)Dec 5Same dayWood Barbara AEVP, Gen. Counsel, Corp. Sec.SSaleClass A Common Stock−2.15K$2.59−$5.58K−3.7%56.3K after
Dec 3, 2021 (view filing)Dec 21 dayStergiou Angelos M.President and CEOSSale−2.12K$6.25−$13.3K−1.7%121.2K after
Dec 3, 2021 (view filing)Dec 21 dayWood Barbara AEVP, Gen. Counsel, Corp. Sec.SSale−847$6.25−$5.29K−2.0%42.0K after
Dec 3, 2021 (view filing)Dec 21 dayBurns John ThomasVP, Finance & Corp ControllerSSale−231$6.27−$1.45K−1.3%17.6K after